![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: E2F3 |
Gene summary for E2F3 |
![]() |
Gene information | Species | Human | Gene symbol | E2F3 | Gene ID | 1871 |
Gene name | E2F transcription factor 3 | |
Gene Alias | E2F-3 | |
Cytomap | 6p22.3 | |
Gene Type | protein-coding | GO ID | GO:0000082 | UniProtAcc | O00716 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1871 | E2F3 | CCI_1 | Human | Cervix | CC | 1.52e-06 | 5.52e-01 | 0.528 |
1871 | E2F3 | CCI_2 | Human | Cervix | CC | 4.34e-11 | 8.19e-01 | 0.5249 |
1871 | E2F3 | CCI_3 | Human | Cervix | CC | 8.39e-12 | 6.92e-01 | 0.516 |
1871 | E2F3 | HTA11_3410_2000001011 | Human | Colorectum | AD | 7.52e-09 | -4.28e-01 | 0.0155 |
1871 | E2F3 | HTA11_78_2000001011 | Human | Colorectum | AD | 1.60e-03 | -3.55e-01 | -0.1088 |
1871 | E2F3 | HTA11_3361_2000001011 | Human | Colorectum | AD | 3.72e-03 | -4.63e-01 | -0.1207 |
1871 | E2F3 | HTA11_696_2000001011 | Human | Colorectum | AD | 2.39e-05 | -3.88e-01 | -0.1464 |
1871 | E2F3 | HTA11_866_2000001011 | Human | Colorectum | AD | 2.44e-02 | -3.04e-01 | -0.1001 |
1871 | E2F3 | HTA11_866_3004761011 | Human | Colorectum | AD | 7.45e-03 | -3.64e-01 | 0.096 |
1871 | E2F3 | HTA11_7696_3000711011 | Human | Colorectum | AD | 9.51e-08 | -3.53e-01 | 0.0674 |
1871 | E2F3 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 9.07e-04 | -3.16e-01 | 0.3859 |
1871 | E2F3 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 2.92e-05 | -3.88e-01 | 0.3005 |
1871 | E2F3 | A001-C-207 | Human | Colorectum | FAP | 7.60e-03 | -2.73e-01 | 0.1278 |
1871 | E2F3 | A015-C-203 | Human | Colorectum | FAP | 2.07e-25 | -4.04e-01 | -0.1294 |
1871 | E2F3 | A015-C-204 | Human | Colorectum | FAP | 7.06e-06 | -3.42e-01 | -0.0228 |
1871 | E2F3 | A014-C-040 | Human | Colorectum | FAP | 1.44e-07 | -5.97e-01 | -0.1184 |
1871 | E2F3 | A002-C-201 | Human | Colorectum | FAP | 1.48e-08 | -2.65e-01 | 0.0324 |
1871 | E2F3 | A002-C-203 | Human | Colorectum | FAP | 2.26e-04 | -2.04e-01 | 0.2786 |
1871 | E2F3 | A001-C-119 | Human | Colorectum | FAP | 3.80e-08 | -3.94e-01 | -0.1557 |
1871 | E2F3 | A001-C-108 | Human | Colorectum | FAP | 1.37e-15 | -3.73e-01 | -0.0272 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00725949 | Cervix | CC | establishment of protein localization to organelle | 99/2311 | 422/18723 | 1.23e-10 | 2.11e-08 | 99 |
GO:00069139 | Cervix | CC | nucleocytoplasmic transport | 71/2311 | 301/18723 | 4.04e-08 | 2.54e-06 | 71 |
GO:00511699 | Cervix | CC | nuclear transport | 71/2311 | 301/18723 | 4.04e-08 | 2.54e-06 | 71 |
GO:00345048 | Cervix | CC | protein localization to nucleus | 68/2311 | 290/18723 | 9.91e-08 | 5.25e-06 | 68 |
GO:00447725 | Cervix | CC | mitotic cell cycle phase transition | 89/2311 | 424/18723 | 2.70e-07 | 1.12e-05 | 89 |
GO:00170388 | Cervix | CC | protein import | 48/2311 | 206/18723 | 8.62e-06 | 1.98e-04 | 48 |
GO:00000824 | Cervix | CC | G1/S transition of mitotic cell cycle | 49/2311 | 214/18723 | 1.16e-05 | 2.48e-04 | 49 |
GO:00448434 | Cervix | CC | cell cycle G1/S phase transition | 53/2311 | 241/18723 | 1.76e-05 | 3.32e-04 | 53 |
GO:00511707 | Cervix | CC | import into nucleus | 38/2311 | 159/18723 | 3.98e-05 | 6.18e-04 | 38 |
GO:00066067 | Cervix | CC | protein import into nucleus | 37/2311 | 155/18723 | 5.13e-05 | 7.71e-04 | 37 |
GO:0072594 | Colorectum | AD | establishment of protein localization to organelle | 148/3918 | 422/18723 | 7.95e-12 | 1.04e-09 | 148 |
GO:0006913 | Colorectum | AD | nucleocytoplasmic transport | 102/3918 | 301/18723 | 1.00e-07 | 4.85e-06 | 102 |
GO:0051169 | Colorectum | AD | nuclear transport | 102/3918 | 301/18723 | 1.00e-07 | 4.85e-06 | 102 |
GO:0034504 | Colorectum | AD | protein localization to nucleus | 94/3918 | 290/18723 | 2.83e-06 | 8.09e-05 | 94 |
GO:0017038 | Colorectum | AD | protein import | 67/3918 | 206/18723 | 6.34e-05 | 1.05e-03 | 67 |
GO:0051170 | Colorectum | AD | import into nucleus | 53/3918 | 159/18723 | 1.76e-04 | 2.38e-03 | 53 |
GO:0006606 | Colorectum | AD | protein import into nucleus | 51/3918 | 155/18723 | 3.29e-04 | 3.86e-03 | 51 |
GO:00725942 | Colorectum | MSS | establishment of protein localization to organelle | 139/3467 | 422/18723 | 5.75e-13 | 1.12e-10 | 139 |
GO:00069132 | Colorectum | MSS | nucleocytoplasmic transport | 99/3467 | 301/18723 | 1.35e-09 | 1.03e-07 | 99 |
GO:00511692 | Colorectum | MSS | nuclear transport | 99/3467 | 301/18723 | 1.35e-09 | 1.03e-07 | 99 |
Page: 1 2 3 4 5 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa052125 | Colorectum | FAP | Pancreatic cancer | 24/1404 | 76/8465 | 8.95e-04 | 5.20e-03 | 3.16e-03 | 24 |
hsa051637 | Colorectum | FAP | Human cytomegalovirus infection | 55/1404 | 225/8465 | 1.42e-03 | 7.67e-03 | 4.67e-03 | 55 |
hsa052153 | Colorectum | FAP | Prostate cancer | 28/1404 | 97/8465 | 1.67e-03 | 8.57e-03 | 5.21e-03 | 28 |
hsa052255 | Colorectum | FAP | Hepatocellular carcinoma | 43/1404 | 168/8465 | 1.78e-03 | 8.99e-03 | 5.47e-03 | 43 |
hsa052205 | Colorectum | FAP | Chronic myeloid leukemia | 23/1404 | 76/8465 | 2.14e-03 | 1.05e-02 | 6.39e-03 | 23 |
hsa052231 | Colorectum | FAP | Non-small cell lung cancer | 20/1404 | 72/8465 | 1.14e-02 | 3.92e-02 | 2.38e-02 | 20 |
hsa052223 | Colorectum | FAP | Small cell lung cancer | 24/1404 | 92/8465 | 1.33e-02 | 4.46e-02 | 2.71e-02 | 24 |
hsa041101 | Colorectum | FAP | Cell cycle | 37/1404 | 157/8465 | 1.44e-02 | 4.77e-02 | 2.90e-02 | 37 |
hsa052256 | Colorectum | CRC | Hepatocellular carcinoma | 37/1091 | 168/8465 | 6.38e-04 | 5.89e-03 | 3.99e-03 | 37 |
hsa051638 | Colorectum | CRC | Human cytomegalovirus infection | 45/1091 | 225/8465 | 1.54e-03 | 1.17e-02 | 7.94e-03 | 45 |
hsa052206 | Colorectum | CRC | Chronic myeloid leukemia | 18/1091 | 76/8465 | 6.86e-03 | 3.37e-02 | 2.28e-02 | 18 |
hsa052154 | Colorectum | CRC | Prostate cancer | 21/1091 | 97/8465 | 1.08e-02 | 4.74e-02 | 3.21e-02 | 21 |
hsa052257 | Colorectum | CRC | Hepatocellular carcinoma | 37/1091 | 168/8465 | 6.38e-04 | 5.89e-03 | 3.99e-03 | 37 |
hsa051639 | Colorectum | CRC | Human cytomegalovirus infection | 45/1091 | 225/8465 | 1.54e-03 | 1.17e-02 | 7.94e-03 | 45 |
hsa052207 | Colorectum | CRC | Chronic myeloid leukemia | 18/1091 | 76/8465 | 6.86e-03 | 3.37e-02 | 2.28e-02 | 18 |
hsa052155 | Colorectum | CRC | Prostate cancer | 21/1091 | 97/8465 | 1.08e-02 | 4.74e-02 | 3.21e-02 | 21 |
hsa0411023 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa05166211 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa05169210 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa0421829 | Esophagus | ESCC | Cellular senescence | 119/4205 | 156/8465 | 5.89e-12 | 9.40e-11 | 4.81e-11 | 119 |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
E2F3 | SNV | Missense_Mutation | novel | c.1178C>A | p.Ser393Tyr | p.S393Y | O00716 | protein_coding | deleterious(0.02) | benign(0.374) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
E2F3 | SNV | Missense_Mutation | c.1391N>A | p.Cys464Tyr | p.C464Y | O00716 | protein_coding | tolerated_low_confidence(0.26) | benign(0.003) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
E2F3 | insertion | In_Frame_Ins | novel | c.693_694insTCCTTTAGTTCATGCATTAGGCAATCCACAAATTGTGTGACACTA | p.Ile231_Lys232insSerPheSerSerCysIleArgGlnSerThrAsnCysValThrLeu | p.I231_K232insSFSSCIRQSTNCVTL | O00716 | protein_coding | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
E2F3 | deletion | Frame_Shift_Del | novel | c.523_524delGA | p.Glu175LysfsTer5 | p.E175Kfs*5 | O00716 | protein_coding | TCGA-AR-A5QQ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD | ||
E2F3 | SNV | Missense_Mutation | novel | c.470G>A | p.Gly157Glu | p.G157E | O00716 | protein_coding | deleterious(0.02) | benign(0.438) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
E2F3 | SNV | Missense_Mutation | c.180C>G | p.Ile60Met | p.I60M | O00716 | protein_coding | tolerated(0.14) | benign(0) | TCGA-C5-A1MJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
E2F3 | SNV | Missense_Mutation | c.473G>A | p.Arg158Lys | p.R158K | O00716 | protein_coding | tolerated(0.35) | benign(0.066) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
E2F3 | SNV | Missense_Mutation | rs765868574 | c.485N>A | p.Arg162Gln | p.R162Q | O00716 | protein_coding | tolerated(0.44) | benign(0.119) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
E2F3 | SNV | Missense_Mutation | c.877N>T | p.Asn293Tyr | p.N293Y | O00716 | protein_coding | deleterious(0) | benign(0.253) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
E2F3 | SNV | Missense_Mutation | novel | c.1103A>T | p.His368Leu | p.H368L | O00716 | protein_coding | tolerated(0.76) | benign(0.027) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |